Celldex Therapeutics, Inc.(CLDX)

$35.26▲1.17 (3.43%)

Chart

Celldex Therapeutics, Inc.(CLDX)

NASDAQ

$35.26▲1.17 (3.43%)

Chart Studio

CLDX(CLDX)

CLDX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-1.04

Aug 6, 2026 · Reports before open

Revenue Estimate

$735,750

FY2030E EPS$3.88

Analyst Sentiment

Wall St. Consensus

Buy

18 analysts·Moderate coverage

Score

17 Buy (94%)1 Hold (6%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1794%

Hold

16%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$45.00

+27.6%

Consensus

$48.00

+36.1%

Bull

$54.00

+53.1%

12-Month Target Range18 analysts

$45.00$48.00$54.00

Current $35.26Consensus

Current Price

$35.26

Upside to Consensus

$12.74

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+400.14%

EPS—

FY2028

Rev+1279.75%

EPS—

FY2029

Rev+232.82%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$11M	$152M	$507M	$963M
Low	$13,064	$3M	$145M	$93M	$177M
High	$6M	$29M	$159M	$1.33B	$2.53B
EBITDA Avg	$-2M	$-11M	$-152M	$-507M	$-963M
Low	$-6M	$-29M	$-159M	$-1.33B	$-2.53B
High	$-13,064	$-3M	$-145M	$-93M	$-177M
EBIT Avg	$-2M	$-11M	$-152M	$-507M	$-963M
Low	$-6M	$-29M	$-159M	$-1.33B	$-2.53B
High	$-13,064	$-3M	$-145M	$-93M	$-177M
Net Income Avg	$-285M	$-302M	$-269M	$-7M	$258M
Low	$-303M	$-356M	$-329M	$-23M	$-16M
High	$-268M	$-247M	$-87M	$456,121	$805M
EPS Avg	$-4.35	$-4.38	$-3.11	$-0.11	$3.88
Low	$-4.56	$-5.36	$-4.95	$-0.35	$-0.24
High	$-4.02	$-3.71	$-1.30	$0.01	$12.11
Analysts (Rev / EPS)	8 / 9	9 / 9	10 / 10	5 / 4	5 / 4

Quarterly

Metric	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$735,750	$803,250	$1M	$880,000	$880,000	$880,000	$880,000
Low	$213,200	$310,935	$394,483	$340,645	$340,645	$340,645	$340,645
High	$1M	$1M	$2M	$1M	$1M	$1M	$1M
EBITDA Avg	$-735,750	$-803,250	$-1M	$-880,000	$-880,000	$-880,000	$-880,000
Low	$-1M	$-1M	$-2M	$-1M	$-1M	$-1M	$-1M
High	$-213,200	$-310,935	$-394,483	$-340,645	$-340,645	$-340,645	$-340,645
EBIT Avg	$-735,750	$-803,250	$-1M	$-880,000	$-880,000	$-880,000	$-880,000
Low	$-1M	$-1M	$-2M	$-1M	$-1M	$-1M	$-1M
High	$-213,200	$-310,935	$-394,483	$-340,645	$-340,645	$-340,645	$-340,645
Net Income Avg	$-70M	$-71M	$-71M	$-63M	$-65M	$-69M	$-74M
Low	$-72M	$-75M	$-128M	$-114M	$-116M	$-124M	$-133M
High	$-69M	$-69M	$-14M	$-13M	$-13M	$-14M	$-15M
EPS Avg	$-1.06	$-1.07	$-1.07	$-0.95	$-0.97	$-1.03	$-1.11
Low	$-1.08	$-1.12	$-1.92	$-1.71	$-1.74	$-1.86	$-2.00
High	$-1.04	$-1.04	$-0.22	$-0.19	$-0.20	$-0.21	$-0.23
Analysts (Rev / EPS)	6 / 6	6 / 7	5 / 3	3 / 3	3 / 2	3 / 2	3 / 2

Earnings Surprises

Recent Analyst Actions

Jun 10, 2026UBS

Celldex price target raised to $45 from $38 at UBS

Target:$45.00

+49.0%from $30.21

May 13, 2026Wells Fargo

Celldex price target raised to $54 from $38 at Wells Fargo

Target:$54.00

+68.8%from $32.00

May 8, 2026Barclays

Celldex price target raised to $48 from $45 at Barclays

Target:$48.00

+44.1%from $33.32

Apr 20, 2026Barclays

Celldex upgraded to Overweight from Underweight at Barclays

Target:$45.00

+30.2%from $34.55

Dec 17, 2025Barclays

Celldex price target raised to $24 from $21 at Barclays

Target:$24.00

-10.0%from $26.68

Nov 11, 2025Barclays

Celldex price target lowered to $21 from $25 at Barclays

Target:$21.00

-7.4%from $22.67

Oct 13, 2025Barclays

Celldex initiated with an Underweight at Barclays

Target:$25.00

-6.6%from $26.77

Mar 20, 2025Morgan Stanley

Celldex initiated with an Overweight at Morgan Stanley

Target:$46.00

+131.4%from $19.88

Oct 29, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)

Target:$80.00

+195.0%from $27.11

Sep 25, 2024Wells Fargo

Celldex upgraded to Overweight from Equal Weight at Wells Fargo

Target:$44.00

+22.2%from $36.02

Jun 17, 2024Stifel Nicolaus

Celldex initiated with a Buy at Stifel

Target:$58.00

+66.1%from $34.91

Nov 10, 2023Wells Fargo

Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight

Target:$27.00

+4.7%from $25.78

Nov 11, 2022Guggenheim

Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63

Target:$63.00

+57.9%from $39.89

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance